Michael von Forstner | Chief Scientific Officer
MedGenie

Michael von Forstner is a seasoned pharma/biotech executive with over 25 years of experience in drug development with a focus on strategic patient safety and pharmacovigilance. As the Chief Scientific Officer at MedGenie, he is responsible for the development of innovative digital health solutions supporting the optimization of the personal benefit-risk profiles of treatment pathways for patients. Michael is known for his innovative approaches to drug safety, leveraging technology and data analytics to drive performance and improve patient outcomes which has led to several "industry firsts" over the years. With a keen interest in integrating patient preference information in the development process and a strong background in immunology and oncology drug development, he is dedicated to advancing patient safety practices and to fostering partnerships within the industry and with academic partners. Michael is also a member of the Royal Society of Medicine's Digital Health Council with a focus on the development and use of Digital Twins/Virtual Humans to improve patient safety. Michael's expertise and leadership make him a valuable asset in the field of drug safety, and his insights are highly sought after in conferences and events like the World Drug Safety Congress Americas.